Drugmaker AstraZeneca <a href="https://www.reuters.com/companies/AZN.L/"target="_blank">(AZN.L)</a> is drafting a plan to spin off its China business, and listing a separate unit in Hong Kong is being viewed as an option, the Financial Times reported on Sunda…